In our patient cohort, three patients with HER2-positive BTC completed HER2-targeted chemotherapy, and clinical anti-tumor activity was observed in all of them: two patients demonstrated a partial response, and the other one showed stable disease for 18 weeks. Here, ERBB2 is linked to neoplasm.